DiaMedica Therapeutics (DMAC) Competitors $5.21 -0.25 (-4.58%) As of 12:32 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends DMAC vs. GYRE, AVBP, QURE, BCAX, IMTX, REPL, ETNB, PAHC, PLRX, and TYRAShould you be buying DiaMedica Therapeutics stock or one of its competitors? The main competitors of DiaMedica Therapeutics include Gyre Therapeutics (GYRE), ArriVent BioPharma (AVBP), uniQure (QURE), Bicara Therapeutics (BCAX), Immatics (IMTX), Replimune Group (REPL), 89bio (ETNB), Phibro Animal Health (PAHC), Pliant Therapeutics (PLRX), and Tyra Biosciences (TYRA). These companies are all part of the "pharmaceutical products" industry. DiaMedica Therapeutics vs. Gyre Therapeutics ArriVent BioPharma uniQure Bicara Therapeutics Immatics Replimune Group 89bio Phibro Animal Health Pliant Therapeutics Tyra Biosciences Gyre Therapeutics (NASDAQ:GYRE) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, community ranking, valuation, institutional ownership, analyst recommendations and media sentiment. Do institutionals and insiders hold more shares of GYRE or DMAC? 24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 19.5% of Gyre Therapeutics shares are held by insiders. Comparatively, 7.2% of DiaMedica Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media prefer GYRE or DMAC? In the previous week, Gyre Therapeutics had 4 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 6 mentions for Gyre Therapeutics and 2 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.88 beat Gyre Therapeutics' score of 0.30 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Gyre Therapeutics Neutral DiaMedica Therapeutics Very Positive Which has higher valuation & earnings, GYRE or DMAC? DiaMedica Therapeutics has lower revenue, but higher earnings than Gyre Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGyre Therapeutics$105.03M8.84-$92.93MN/AN/ADiaMedica TherapeuticsN/AN/A-$19.38M-$0.56-9.55 Does the MarketBeat Community prefer GYRE or DMAC? DiaMedica Therapeutics received 93 more outperform votes than Gyre Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformGyre TherapeuticsN/AN/ADiaMedica TherapeuticsOutperform Votes9362.84% Underperform Votes5537.16% Is GYRE or DMAC more profitable? DiaMedica Therapeutics has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -84.57%. DiaMedica Therapeutics' return on equity of -43.67% beat Gyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gyre Therapeutics-84.57% -118.43% -71.97% DiaMedica Therapeutics N/A -43.67%-40.81% Which has more risk & volatility, GYRE or DMAC? Gyre Therapeutics has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Do analysts prefer GYRE or DMAC? DiaMedica Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 30.84%. Given DiaMedica Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe DiaMedica Therapeutics is more favorable than Gyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00DiaMedica Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryDiaMedica Therapeutics beats Gyre Therapeutics on 9 of the 14 factors compared between the two stocks. Get DiaMedica Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DMAC vs. The Competition Export to ExcelMetricDiaMedica TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$228.77M$6.65B$5.28B$8.89BDividend YieldN/A2.91%5.24%3.95%P/E Ratio-9.5510.4686.9216.97Price / SalesN/A196.241,072.20123.76Price / CashN/A57.7043.2437.84Price / Book3.965.055.124.95Net Income-$19.38M$153.41M$121.99M$227.40M7 Day Performance-3.78%-4.27%-2.11%-2.91%1 Month Performance3.68%-4.87%18.34%-0.25%1 Year Performance78.93%-2.02%25.78%14.13% DiaMedica Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DMACDiaMedica Therapeutics1.9898 of 5 stars$5.21-4.6%$7.00+34.4%+85.7%$222.79MN/A-9.3020Positive NewsGYREGyre Therapeutics0.213 of 5 stars$9.98-7.5%N/A-58.7%$933.34M$105.03M0.0040AVBPArriVent BioPharma1.1492 of 5 stars$26.20-4.8%$36.80+40.5%N/A$882.86MN/A0.0040Positive NewsGap DownQUREuniQure3.582 of 5 stars$17.95+0.1%$33.88+88.7%+140.5%$874.94M$28.59M-3.62500News CoverageBCAXBicara TherapeuticsN/A$16.05-3.8%$43.00+167.9%N/A$873.38MN/A0.0032Positive NewsIMTXImmatics1.3851 of 5 stars$7.26+1.3%$16.67+129.6%-42.7%$866.53M$115.50M-11.00260REPLReplimune Group3.9882 of 5 stars$12.48-1.1%$17.29+38.5%+23.8%$853.84MN/A-4.09210Positive NewsETNB89bio1.4898 of 5 stars$7.97+0.1%$30.33+280.6%-37.3%$845.82MN/A-2.7440Positive NewsPAHCPhibro Animal Health3.9161 of 5 stars$20.67+0.7%$20.50-0.8%+90.9%$837.20M$1.05B48.071,940Analyst RevisionPLRXPliant Therapeutics3.7368 of 5 stars$13.46-0.5%$40.50+200.9%-30.9%$819.10M$1.58M-4.0390TYRATyra Biosciences2.2983 of 5 stars$16.03+2.6%$31.00+93.4%+36.1%$811.17MN/A-9.9620Analyst ForecastNews Coverage Related Companies and Tools Related Companies Gyre Therapeutics Alternatives ArriVent BioPharma Alternatives uniQure Alternatives Bicara Therapeutics Alternatives Immatics Alternatives Replimune Group Alternatives 89bio Alternatives Phibro Animal Health Alternatives Pliant Therapeutics Alternatives Tyra Biosciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DMAC) was last updated on 1/10/2025 by MarketBeat.com Staff From Our PartnersHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredShocker: Trump’s 1st Day Could Change EverythingA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredLIMITED TIME OFFER — Weiss’ gold playbookIt's critical you get all the critical facts BEFORE the Gold Bull Market Summit recording goes offline. Do ...Weiss Ratings | SponsoredKamala’s final humiliation These ten investments legendary financial analyst Porter Stansberry is exposing after he spent time at Mar-a-L...Porter & Company | SponsoredBuy this Stock before Trump Takes Office!We're issuing an urgent "buy alert" on a little-known "AI company" set to SOAR under this new administration. ...Behind the Markets | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
